Company / Gross Profit
NovaBay Pharmaceuticals, Inc. Gross Profit History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$6.5M
FY2024
5-year range
$6.0M / $7.8M
FY2020-FY2024
Trend
+6.5%
vs FY2023
Sector context
#27 of 27
Health Care
What the data says
Among 27 Health Care companies, NovaBay Pharmaceuticals, Inc. is in the bottom 0% for gross profit. Gross Profit has fluctuated over the past 10 years, ranging from $3M in FY2015 to $15M in FY2017.
Based on SEC 10-K filings.
$6M in FY2024 with a 5-year CAGR of +5.9%.
Declined from $8M to $6M over the past 2 years.
Health Care sector context is included.
Gross Profit over time
Growth rates
- 3-Year CAGR
- -0.2%
- 5-Year CAGR
- +5.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 0% in Health CareTop 100% of 27This company $6.5M Sector average $3.7B
▼
-99.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.9%, indicating consistent growth.
- In FY2024, gross profit increased 6.5% year-over-year.
- Ranks #27 out of 27 companies in the Health Care sector.
- Peak gross profit was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $6.5M | +6.5% |
| FY2023 | $6.1M | -21.8% |
| FY2022 | $7.8M | +19.4% |
| FY2021 | $6.5M | +9.2% |
| FY2020 | $6.0M | +22.7% |
| FY2019 | $4.9M | -55.8% |
| FY2018 | $11.0M | -28.8% |
| FY2017 | $15.4M | +63.7% |
| FY2016 | $9.4M | +202.3% |
| FY2015 | $3.1M | +449.3% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026